Alberto Molano was born in Bogotá, Colombia. He studied medicine at Universidad del Rosario and obtained a Ph.D. in Immunology from Weill Cornell Graduate School of Medical Sciences in New York. He conducted research and authored or co-authored twenty publications on molecular and cellular immunology, autoimmunity, immunology of aging and parasite immunology.
CrystecPharma signed a letter of understanding with Iconovo to develop innovative dry powder inhaler solutions for the treatment of patients with lung diseases, including pulmonary fibrosis. Direct delivery of medications into ... Read more
The demographic and clinical characteristics of patients with idiopathic pulmonary fibrosis (IPF) in Spain are similar to those of IPF patients in other countries, allowing for comparison with other registries ... Read more
Lung Therapeutics announced that it has raised $36 million in Series C financing to fund two projects, including a healthy volunteer Phase 1 clinical trial testing LTI-03, an experimental therapy ... Read more
Measuring three specific biomarkers — nitric oxide, PGE2, and 8‐isoprostane — in the exhaled breath condensates (EBC) or bronchoalveolar lavage fluids (BALF) of patients with different forms of interstitial lung ... Read more
A long-term collaboration was announced to accelerate the discovery of new medicines for idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD) by combining BenevolentAI’s expertise in artificial intelligence (AI) ... Read more
Algernon Pharmaceuticals announced its plans to conduct a new in vivo animal study comparing its lead anti-fibrotic NP-251 compound with clinically relevant doses of both Esbriet (pirfenidone) and Ofev (nintedanib), two approved medicines for the treatment of idiopathic ... Read more
The incidence of lung cancer is greater among patients with idiopathic pulmonary fibrosis (IPF), compared with the general population, and is associated with a worse prognosis, a new U.S. study reports. ... Read more